Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ligand Pharmaceuticals Incorporated - Common Stock
(NQ:
LGND
)
213.44
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ligand Pharmaceuticals Incorporated - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
February 27, 2024
Via
Benzinga
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Earnings Scheduled For February 27, 2024
↗
February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
Via
Benzinga
Ligand Pharmaceuticals's Earnings: A Preview
↗
February 26, 2024
Via
Benzinga
Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®
February 22, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Where Ligand Pharmaceuticals Stands With Analysts
↗
September 19, 2023
Via
Benzinga
Analyst Expectations for Ligand Pharmaceuticals's Future
↗
August 23, 2023
Via
Benzinga
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
February 16, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
February 13, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 01, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum
January 05, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance
December 12, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City
December 06, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications
December 01, 2023
From
Palvella Therapeutics
Via
GlobeNewswire
Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's
↗
November 28, 2023
Merck & Co Inc (NYSE: MRK) released results from the STRIDE-3 Phase 3 trial evaluating V116, the company's investigational 21-valent
Via
Benzinga
Ligand Reports Third Quarter 2023 Financial Results
November 08, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million
November 01, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand To Report Third Quarter 2023 Financial Results On November 8
October 25, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
October 18, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ligand Acquires Assets of Novan, Inc. for $12.2 Million
September 27, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Appoints Martine Zimmermann to its Board of Directors
September 26, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
September 22, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand’s Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control
September 21, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Pharma Updates Annual Guidance As It Spins Out Pelican Subsidiary
↗
September 19, 2023
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) entered into a merger agreement under which its subsidiary, Pelican Technology Holdings Inc, has become a wholly owned subsidiary of Primrose Bio...
Via
Benzinga
Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio
September 18, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
September 01, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Reports Second Quarter 2023 Financial Results
August 08, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand’s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
July 27, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand To Report Second Quarter 2023 Financial Results On August 8
July 25, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Why Are Novan Shares Nosediving Today?
↗
July 17, 2023
Novan Inc (NASDAQ: NOVN) shares are trading lower after Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has offered to
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
